Home > Cardiology > ESC 2021 > Haemodynamic-guided HF management shows benefits in HF hospitalisations

Haemodynamic-guided HF management shows benefits in HF hospitalisations

Presented By
Prof. JoAnn Lindenfeld, Vanderbilt University Medical Center, USA
Conference
ESC 2021
Trial
GUIDE-HF
The GUIDE-HF trial, presented in a Hot Line Session and simultaneously published in The Lancet, showed benefits of haemodynamic-guided heart failure (HF) management with an implantable device in reducing HF hospitalisation [1,2]. However, no influence was observed on urgent HF visits and mortality. The rationale of haemodynamic-guided HF management is that the addition of information about pulmonary artery pressure to clinical signs and symptoms may allow for improved HF management as elevated or increasing pulmonary artery pressure predicts congestion. The single-blind prospective GUIDE-HF (NCT03387813) trial, presented by Prof. JoAnn Lindenfeld (Vanderbilt University Medical Center, TN, USA), assessed this approach in 1,022 patients with NYHA class II–IV HF and either a hospitalisation for HF within the preceding 12 mo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on